跳至主要内容
临床试验/NCT00739401
NCT00739401已完成不适用

Endologix Powerlink® Suprarenal Proximal Cuff

Endologix8 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2006年5月5日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Endologix
入组人数
44
试验地点
8
主要终点
Number of Subjects With Proximal Type I Endoleak

研究概览

简要总结

The use of a suprarenal extension device during the index AAA procedure to accommodate the patient's anatomy and to prevent or repair leakage.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •18 years old
  • •Informed consent understood and signed
  • •Will comply with post-treatment follow-up requirements up to 5 years
  • •Candidate for Powerlink Infrarenal Bifurcated Graft

排除标准

  • •Life expectancy < 2 years
  • •Participating in another clinical research study
  • •Pregnant or lactating women
  • •Patient has other medical or psychiatric problems, which in the opinion of the Investigator, precludes them from participating in the Study
  • •Creatinine level > 1.7mg/dl
  • •Renal transplant patient
  • •Patient with > 75% renal artery stenosis and not eligible for PTA/stent intervention prior to suprarenal device fixation

研究组 & 干预措施

1

Experimental

Test subjects requiring endovascular treatment of abdominal aortic or aorto-iliac aneurysms including a proximal cuff extension.

干预措施: Suprarenal Proximal Cuff Extension (Device)

结局指标

主要结局

Number of Subjects With Proximal Type I Endoleak

时间窗: Within 30 Days

The primary study endpoint is defined as the incidence of type I proximal endoleak at 30 days post-treatment.

次要结局

  • Aneurysm Morphology Changes(30 days)
  • Endoleak(30 days)
  • Number of Participants With Stent Graft Integrity and Performance(30 days)
  • Number of Subjects With Major Adverse Events(Within 30 days)
  • Renal Function(30 days)

研究者

发起方
Endologix
申办方类型
Industry
责任方
Sponsor

研究点 (8)

Loading locations...

相似试验